Volume 21: Issue 5 (Dec 2022): Primary and Secondary Glomerular Diseases

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al.: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8: 1002765, 2012 PubMed

• Crossref
• PubMed
Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, : Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 8: 1002765, 2012 PubMed10.1371/journal.pgen.1002765)| false
• Search Google Scholar
• Export Citation

Yu GZ, Guo L, Dong JF, Shi SF, Liu LJ, Wang JW, et al.: Persistent hematuria and kidney disease progression in IgA nephropathy: A cohort study. Am J Kidney Dis 76: 90–99, 2020 PubMed

• Crossref
• PubMed
Yu GZ, Guo L, Dong JF, Shi SF, Liu LJ, Wang JW, : Persistent hematuria and kidney disease progression in IgA nephropathy: A cohort study. Am J Kidney Dis 76: 90–99, 2020 PubMed10.1053/j.ajkd.2019.11.008)| false
• Search Google Scholar
• Export Citation

Rodrigues JC, Haas M, Reich HN: IgA nephropathy. Clin J Am Soc Nephrol 12: 677–686, 2017 PubMed

• Crossref
• PubMed
Rodrigues JC, Haas M, Reich HN: IgA nephropathy. Clin J Am Soc Nephrol 12: 677–686, 2017 PubMed10.2215/CJN.07420716)| false
• Search Google Scholar
• Export Citation

Barratt J, Feehally J: Treatment of IgA nephropathy. Kidney Int 69: 1934–1938, 2006 PubMed

• Crossref
• PubMed
Barratt J, Feehally J: Treatment of IgA nephropathy. Kidney Int 69: 1934–1938, 2006 PubMed10.1038/sj.ki.5000419)| false
• Search Google Scholar
• Export Citation

Herlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS: IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol 9: 1033–1039, 2014 PubMed

• Crossref
• PubMed
Herlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS: IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol 9: 1033–1039, 2014 PubMed10.2215/CJN.11951113)| false
• Search Google Scholar
• Export Citation

Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, et al.; CureGN Consortium: CureGN study rationale, design, and methods: Establishing a large prospective observational study of glomerular disease. Am J Kidney Dis 73: 218–229, 2019 PubMed

• Crossref
• PubMed
Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, ; CureGN Consortium: CureGN study rationale, design, and methods: Establishing a large prospective observational study of glomerular disease. Am J Kidney Dis 73: 218–229, 2019 PubMed10.1053/j.ajkd.2018.07.020)| false
• Search Google Scholar
• Export Citation

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, et al.; CureGN Consortium: Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN Study. Kidney Int Rep 3: 1373–1384, 2018 PubMed

• Crossref
• PubMed
Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, ; CureGN Consortium: Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN Study. Kidney Int Rep 3: 1373–1384, 2018 PubMed10.1016/j.ekir.2018.07.021)| false
• Search Google Scholar
• Export Citation

Delbarba E, Marasa M, Canetta PA, Piva SE, Chatterjee D, Kil BH, et al.; CureGN Consortium: Persistent disease activity in patients with long-standing glomerular disease. Kidney Int Rep 5: 860–871, 2020 PubMed

• Crossref
• PubMed
Delbarba E, Marasa M, Canetta PA, Piva SE, Chatterjee D, Kil BH, ; CureGN Consortium: Persistent disease activity in patients with long-standing glomerular disease. Kidney Int Rep 5: 860–871, 2020 PubMed10.1016/j.ekir.2020.03.017)| false
• Search Google Scholar
• Export Citation

Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, et al.: Etiology and outcome of crescentic glomerulonephritis from a single center in China: A 10-year review. Am J Kidney Dis 67: 376–383, 2016 PubMed

• Crossref
• PubMed
Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, : Etiology and outcome of crescentic glomerulonephritis from a single center in China: A 10-year review. Am J Kidney Dis 67: 376–383, 2016 PubMed10.1053/j.ajkd.2015.07.034)| false
• Search Google Scholar
• Export Citation

Shima Y, Nakanishi K, Hama T, Mukaiyama H, Sato M, Tanaka Y, et al.: Crescentic IgA nephropathy in children. Pediatr Nephrol 35: 1005–1014, 2020 PubMed

• Crossref
• PubMed
Shima Y, Nakanishi K, Hama T, Mukaiyama H, Sato M, Tanaka Y, : Crescentic IgA nephropathy in children. Pediatr Nephrol 35: 1005–1014, 2020 PubMed10.1007/s00467-020-04483-w)| false
• Search Google Scholar
• Export Citation

Bellur SS, Lepeytre F, Vorobyeva O, Troyanov S, Cook HT, Roberts IS; International IgA Nephropathy Working Group: Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91: 235–243, 2017 PubMed

• Crossref
• PubMed
Bellur SS, Lepeytre F, Vorobyeva O, Troyanov S, Cook HT, Roberts IS; International IgA Nephropathy Working Group: Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91: 235–243, 2017 PubMed10.1016/j.kint.2016.09.029)| false
• Search Google Scholar
• Export Citation

Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al.; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534–545, 2009 PubMed

• Crossref
• PubMed
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, ; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534–545, 2009 PubMed10.1038/ki.2009.243)| false
• Search Google Scholar
• Export Citation

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al.; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants: Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 91: 1014–1021, 2017 PubMed

• Crossref
• PubMed
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, ; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants: Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 91: 1014–1021, 2017 PubMed10.1016/j.kint.2017.02.003)| false
• Search Google Scholar
• Export Citation

Jullien P, Laurent B, Berthoux F, Masson I, Dinic M, Claisse G, et al.: Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant 35: 1179–1186, 2020 PubMed

• Crossref
• PubMed
Jullien P, Laurent B, Berthoux F, Masson I, Dinic M, Claisse G, : Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant 35: 1179–1186, 2020 PubMed10.1093/ndt/gfy341)| false
• Search Google Scholar
• Export Citation

Cai Q, Shi S, Wang S, Ren Y, Hou W, Liu L, et al.: Microangiopathic lesions in IgA nephropathy: A cohort study. Am J Kidney Dis 74: 629–639, 2019 PubMed

• Crossref
• PubMed
Cai Q, Shi S, Wang S, Ren Y, Hou W, Liu L, : Microangiopathic lesions in IgA nephropathy: A cohort study. Am J Kidney Dis 74: 629–639, 2019 PubMed10.1053/j.ajkd.2019.03.416)| false
• Search Google Scholar
• Export Citation

Satoskar AA, Suleiman S, Ayoub I, Hemminger J, Parikh S, Brodsky SV, et al.: Staphylococcus infection-associated GN: Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol 12: 39–49, 2017 PubMed

• Crossref
• PubMed
Satoskar AA, Suleiman S, Ayoub I, Hemminger J, Parikh S, Brodsky SV, : Staphylococcus infection-associated GN: Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol 12: 39–49, 2017 PubMed10.2215/CJN.05070516)| false
• Search Google Scholar
• Export Citation

Satoskar AA, Molenda M, Scipio P, Shim R, Zirwas M, Variath RS, et al.: Henoch-Schönlein purpura-like presentation in IgA-dominant Staphylococcus infection - associated glomerulonephritis - a diagnostic pitfall [published correction appears in Clin Nephrol 79: 504, 2013]. Clin Nephrol 79: 302–312, 2013 PubMed

• Crossref
• PubMed
Satoskar AA, Molenda M, Scipio P, Shim R, Zirwas M, Variath RS, : Henoch-Schönlein purpura-like presentation in IgA-dominant Staphylococcus infection - associated glomerulonephritis - a diagnostic pitfall [published correction appears in Clin Nephrol 79: 504, 2013]. Clin Nephrol 79: 302–312, 2013 PubMed10.5414/CN107756)| false
• Search Google Scholar
• Export Citation

Brodsky SV, Nadasdy T, Cassol C, Satoskar A: IgA staining patterns differentiate between IgA nephropathy and IgA-dominant infection-associated glomerulonephritis. Kidney Int Rep 5: 909–911, 2020 PubMed

• Crossref
• PubMed
Brodsky SV, Nadasdy T, Cassol C, Satoskar A: IgA staining patterns differentiate between IgA nephropathy and IgA-dominant infection-associated glomerulonephritis. Kidney Int Rep 5: 909–911, 2020 PubMed10.1016/j.ekir.2020.03.029)| false
• Search Google Scholar
• Export Citation

Reily C, Stewart TJ, Renfrow MB, Novak J: Glycosylation in health and disease. Nat Rev Nephrol 15: 346–366, 2019 PubMed

• Crossref
• PubMed
Reily C, Stewart TJ, Renfrow MB, Novak J: Glycosylation in health and disease. Nat Rev Nephrol 15: 346–366, 2019 PubMed10.1038/s41581-019-0129-4)| false
• Search Google Scholar
• Export Citation

Novak J, Barratt J, Julian BA, Renfrow MB: Aberrant glycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol 38: 461–476, 2018 PubMed

• Crossref
• PubMed
Novak J, Barratt J, Julian BA, Renfrow MB: Aberrant glycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol 38: 461–476, 2018 PubMed10.1016/j.semnephrol.2018.05.016)| false
• Search Google Scholar
• Export Citation

Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al.: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19: 1008–1014, 2008 PubMed

• Crossref
• PubMed
Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, : Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19: 1008–1014, 2008 PubMed10.1681/ASN.2007091052)| false
• Search Google Scholar
• Export Citation

Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, et al.: GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13: 1006609, 2017 PubMed

• Crossref
• PubMed
Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, : GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13: 1006609, 2017 PubMed10.1371/journal.pgen.1006609)| false
• Search Google Scholar
• Export Citation

Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, et al.: Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol 28: 2158–2166, 2017 PubMed

• Crossref
• PubMed
Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, : Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol 28: 2158–2166, 2017 PubMed10.1681/ASN.2016091043)| false
• Search Google Scholar
• Export Citation

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al.: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 2014 PubMed

• Crossref
• PubMed
Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, : Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 2014 PubMed10.1038/ng.3118)| false
• Search Google Scholar
• Export Citation

Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, et al.: Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90: 587–596, 2015 PubMed

• Crossref
• PubMed
Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, : Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90: 587–596, 2015 PubMed10.1016/j.mayocp.2015.01.024)| false
• Search Google Scholar
• Export Citation

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, et al.: Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019 PubMed

• Crossref
• PubMed
Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, : Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019 PubMed10.2215/CJN.08600718)| false
• Search Google Scholar
• Export Citation

Knoop T, Vikse BE, Mwakimonga A, Leh S, Bjørneklett R: Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 32: 1841–1850, 2017 PubMed

• Crossref
• PubMed
Knoop T, Vikse BE, Mwakimonga A, Leh S, Bjørneklett R: Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 32: 1841–1850, 2017 PubMed10.1093/ndt/gfx242)| false
• Search Google Scholar
• Export Citation

Bobart SA, Alexander MP, Shawwa K, Vaughan LE, Ghamrawi R, Sethi S, et al.: The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant 36: 840–847, 2021 PubMed

• Crossref
• PubMed
Bobart SA, Alexander MP, Shawwa K, Vaughan LE, Ghamrawi R, Sethi S, : The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant 36: 840–847, 2021 PubMed10.1093/ndt/gfz267)| false
• Search Google Scholar
• Export Citation

Sim JJ, Bhandari SK, Batech M, Hever A, Harrison TN, Shu YH, et al.: End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population. Mayo Clin Proc 93: 167–178, 2018 PubMed

• Crossref
• PubMed
Sim JJ, Bhandari SK, Batech M, Hever A, Harrison TN, Shu YH, : End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population. Mayo Clin Proc 93: 167–178, 2018 PubMed10.1016/j.mayocp.2017.10.021)| false
• Search Google Scholar
• Export Citation

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al.; International IgA Nephropathy Network: Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 179: 942–952, 2019 PubMed

• Crossref
• PubMed
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, ; International IgA Nephropathy Network: Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 179: 942–952, 2019 PubMed10.1001/jamainternmed.2019.0600)| false
• Search Google Scholar
• Export Citation

Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al.; International IgA Nephropathy Network: Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int 102: 160–172, 2022 PubMed

• Crossref
• PubMed
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, ; International IgA Nephropathy Network: Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int 102: 160–172, 2022 PubMed10.1016/j.kint.2022.02.042)| false
• Search Google Scholar
• Export Citation

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100: 753–779, 2021 PubMed

• Crossref
• PubMed
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, : Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100: 753–779, 2021 PubMed10.1016/j.kint.2021.05.015)| false
• Search Google Scholar
• Export Citation

Coppo R, D’Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, et al.; ERA-EDTA Immunonephrology Working Group: Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant 35: 1002–1009, 2020 PubMed

• Crossref
• PubMed
Coppo R, D’Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, ; ERA-EDTA Immunonephrology Working Group: Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant 35: 1002–1009, 2020 PubMed10.1093/ndt/gfy302)| false
• Search Google Scholar
• Export Citation

Jarrick S, Lundberg S, Welander A, Carrero JJ, Höijer J, Bottai M, et al.: Mortality in IgA nephropathy: A nationwide population-based cohort study. J Am Soc Nephrol 30: 866–876, 2019 PubMed

• Crossref
• PubMed
Jarrick S, Lundberg S, Welander A, Carrero JJ, Höijer J, Bottai M, : Mortality in IgA nephropathy: A nationwide population-based cohort study. J Am Soc Nephrol 30: 866–876, 2019 PubMed10.1681/ASN.2018101017)| false
• Search Google Scholar
• Export Citation

Praga M, Gutiérrez E, González E, Morales E, Hernández E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578–1583, 2003 PubMed

• Crossref
• PubMed
Praga M, Gutiérrez E, González E, Morales E, Hernández E: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578–1583, 2003 PubMed10.1097/01.ASN.0000068460.37369.DC)| false
• Search Google Scholar
• Export Citation

Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Available at https://kdigo.org/guidelines/gd/. Accessed November 25, 2022

• PubMed
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Available at https://kdigo.org/guidelines/gd/. Accessed November 25, 2022)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 PubMed

• Crossref
• PubMed
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, ; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 PubMed10.1056/NEJMoa2024816)| false
• Search Google Scholar
• Export Citation

Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M, et al.: The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol 17: 555–562, 2013 PubMed

• Crossref
• PubMed
Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M, : The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol 17: 555–562, 2013 PubMed10.1007/s10157-012-0744-x)| false
• Search Google Scholar
• Export Citation

Russo E, Verzola D, Salvidio G, Bonino B, Picciotto D, Drovandi S, et al.: Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: A single-center observational study in Italy. J Hypertens 38: 925–935, 2020 PubMed

• Crossref
• PubMed
Russo E, Verzola D, Salvidio G, Bonino B, Picciotto D, Drovandi S, : Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: A single-center observational study in Italy. J Hypertens 38: 925–935, 2020 PubMed10.1097/HJH.0000000000002354)| false
• Search Google Scholar
• Export Citation

Kanno Y, Okada H, Saruta T, Suzuki H: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 54: 360–365, 2000 PubMed

• PubMed
Kanno Y, Okada H, Saruta T, Suzuki H: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 54: 360–365, 2000 PubMed)| false
• Search Google Scholar
• Export Citation

Anders HJ, Davis JM, Thurau K: Nephron protection in diabetic kidney disease. N Engl J Med 375: 2096–2098, 2016 PubMed

• Crossref
• PubMed
Anders HJ, Davis JM, Thurau K: Nephron protection in diabetic kidney disease. N Engl J Med 375: 2096–2098, 2016 PubMed10.1056/NEJMcibr1608564)| false
• Search Google Scholar
• Export Citation

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al.; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015 PubMed

• Crossref
• PubMed
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, ; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015 PubMed10.1056/NEJMoa1415463)| false
• Search Google Scholar
• Export Citation

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, et al.; STOP-IgAN Investigators: After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98: 1044–1052, 2020 PubMed

• Crossref
• PubMed
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, ; STOP-IgAN Investigators: After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98: 1044–1052, 2020 PubMed10.1016/j.kint.2020.04.046)| false
• Search Google Scholar
• Export Citation

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al.; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017 PubMed

• Crossref
• PubMed
Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, ; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017 PubMed10.1001/jama.2017.9362)| false
• Search Google Scholar
• Export Citation

Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al.; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022 PubMed

• Crossref
• PubMed
Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, ; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022 PubMed10.1001/jama.2022.5368)| false
• Search Google Scholar
• Export Citation

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, et al.; NEFIGAN Trial Investigators: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389: 2117–2127, 2017 PubMed

• Crossref
• PubMed
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, ; NEFIGAN Trial Investigators: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389: 2117–2127, 2017 PubMed10.1016/S0140-6736(17)30550-0)| false
• Search Google Scholar
• Export Citation

Zand L, Canetta P, Lafayette R, Aslam N, Jan N, Sethi S, et al.: An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney Int Rep 5: 58–65, 2019 PubMed

• Crossref
• PubMed
Zand L, Canetta P, Lafayette R, Aslam N, Jan N, Sethi S, : An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney Int Rep 5: 58–65, 2019 PubMed10.1016/j.ekir.2019.10.007)| false
• Search Google Scholar
• Export Citation

Xiaowei L, Bo W, Li L, Peng Z: Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int Urol Nephrol 52: 129–136, 2020 PubMed

• Crossref
• PubMed
Xiaowei L, Bo W, Li L, Peng Z: Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int Urol Nephrol 52: 129–136, 2020 PubMed10.1007/s11255-019-02329-5)| false
• Search Google Scholar
• Export Citation

Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, et al.: Recurrent glomerulonephritis after kidney transplantation: Risk factors and allograft outcomes. Kidney Int 92: 461–469, 2017 PubMed

• Crossref
• PubMed
Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, : Recurrent glomerulonephritis after kidney transplantation: Risk factors and allograft outcomes. Kidney Int 92: 461–469, 2017 PubMed10.1016/j.kint.2017.03.015)| false
• Search Google Scholar
• Export Citation

O’Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC: Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 28: 632–644, 2017 PubMed

• Crossref
• PubMed
O’Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC: Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 28: 632–644, 2017 PubMed10.1681/ASN.2016020126)| false
• Search Google Scholar
• Export Citation

Kousios A, Duncan N, Charif R, Tam FWK, Levy J, Cook HT, et al.: Autologous stem cell transplant for the treatment of type I crystal cryoglobulinemic glomerulonephritis caused by monoclonal gammopathy of renal significance (MGRS). Kidney Int Rep 4: 1342–1348, 2019 PubMed

• Crossref
• PubMed
Kousios A, Duncan N, Charif R, Tam FWK, Levy J, Cook HT, : Autologous stem cell transplant for the treatment of type I crystal cryoglobulinemic glomerulonephritis caused by monoclonal gammopathy of renal significance (MGRS). Kidney Int Rep 4: 1342–1348, 2019 PubMed10.1016/j.ekir.2019.05.014)| false
• Search Google Scholar
• Export Citation

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al.: Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol 13: 406–413, 2018 PubMed

• Crossref
• PubMed
Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, : Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol 13: 406–413, 2018 PubMed10.2215/CJN.09080817)| false
• Search Google Scholar
• Export Citation

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, et al.: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93: 977–985, 2018 PubMed

• Crossref
• PubMed
Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, : C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93: 977–985, 2018 PubMed10.1016/j.kint.2017.10.022)| false
• Search Google Scholar
• Export Citation

Medjeral-Thomas N, Malik TH, Patel MP, Toth T, Cook HT, Tomson C, et al.: A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 85: 933–937, 2014 PubMed

• Crossref
• PubMed
Medjeral-Thomas N, Malik TH, Patel MP, Toth T, Cook HT, Tomson C, : A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 85: 933–937, 2014 PubMed10.1038/ki.2013.348)| false
• Search Google Scholar
• Export Citation

Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulonephritis with a severe crescentic phenotype. Pediatr Nephrol 32: 1625–1633, 2017 PubMed

• Crossref
• PubMed
Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulonephritis with a severe crescentic phenotype. Pediatr Nephrol 32: 1625–1633, 2017 PubMed10.1007/s00467-017-3702-8)| false
• Search Google Scholar
• Export Citation

Riedl M, Thorner P, Licht C: C3 glomerulopathy. Pediatr Nephrol 32: 43–57, 2017 PubMed

• Crossref
• PubMed
Riedl M, Thorner P, Licht C: C3 glomerulopathy. Pediatr Nephrol 32: 43–57, 2017 PubMed10.1007/s00467-015-3310-4)| false
• Search Google Scholar
• Export Citation

Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, et al.; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis 77: 684–695, 2021 PubMed

• Crossref
• PubMed
Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, ; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis 77: 684–695, 2021 PubMed10.1053/j.ajkd.2020.11.011)| false
• Search Google Scholar
• Export Citation

Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, et al.: C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 15: 129–143, 2019 PubMed

• Crossref
• PubMed
Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, : C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 15: 129–143, 2019 PubMed10.1038/s41581-018-0107-2)| false
• Search Google Scholar
• Export Citation

Gomes-Alves I, Castro-Ferreira I: C3 glomerulonephritis associated with monoclonal gammopathy of renal significance. Acta Med Port 34: 372–377, 2021 PubMed

• Crossref
• PubMed
Gomes-Alves I, Castro-Ferreira I: C3 glomerulonephritis associated with monoclonal gammopathy of renal significance. Acta Med Port 34: 372–377, 2021 PubMed10.20344/amp.13823)| false
• Search Google Scholar
• Export Citation

Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, et al.: A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 92: 876–887, 2017 PubMed

• Crossref
• PubMed
Togarsimalemath SK, Sethi SK, Duggal R, Le Quintrec M, Jha P, Daniel R, : A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 92: 876–887, 2017 PubMed10.1016/j.kint.2017.04.025)| false
• Search Google Scholar
• Export Citation

Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, et al.: C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434–2446, 2013 PubMed

• Crossref
• PubMed
Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, : C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123: 2434–2446, 2013 PubMed10.1172/JCI68280)| false
• Search Google Scholar
• Export Citation

Wang X, Van Lookeren Campagne M, Katschke Jr. KJ, Gullipalli D, Miwa T, Ueda Y, et al.: Prevention of fatal C3 glomerulopathy by recombinant complement receptor of the Ig superfamily. J Am Soc Nephrol 29: 2053–2059, 2018 PubMed

• Crossref
• PubMed
Wang X, Van Lookeren Campagne M, Katschke Jr. KJ, Gullipalli D, Miwa T, Ueda Y, : Prevention of fatal C3 glomerulopathy by recombinant complement receptor of the Ig superfamily. J Am Soc Nephrol 29: 2053–2059, 2018 PubMed10.1681/ASN.2018030270)| false
• Search Google Scholar
• Export Citation

Andeen NK, Yang HY, Dai DF, MacCoss MJ, Smith KD: DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 29: 231–239, 2018 PubMed

• Crossref
• PubMed
Andeen NK, Yang HY, Dai DF, MacCoss MJ, Smith KD: DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 29: 231–239, 2018 PubMed10.1681/ASN.2017050566)| false
• Search Google Scholar
• Export Citation

Hogan JJ, Alexander MP, Leung N: Dysproteinemia and the kidney: Core curriculum 2019. Am J Kidney Dis 74: 822–836, 2019 PubMed

• Crossref
• PubMed
Hogan JJ, Alexander MP, Leung N: Dysproteinemia and the kidney: Core curriculum 2019. Am J Kidney Dis 74: 822–836, 2019 PubMed10.1053/j.ajkd.2019.04.029)| false
• Search Google Scholar
• Export Citation

Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 94: 178–186, 2018 PubMed

• Crossref
• PubMed
Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 94: 178–186, 2018 PubMed10.1016/j.kint.2018.01.037)| false
• Search Google Scholar
• Export Citation

Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, et al.; MPGN/DDD/C3 Glomerulopathy Rare Disease Group; NIHR BioResource: Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy. J Am Soc Nephrol 31: 365–373, 2020 PubMed

• Crossref
• PubMed
Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, ; MPGN/DDD/C3 Glomerulopathy Rare Disease Group; NIHR BioResource: Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy. J Am Soc Nephrol 31: 365–373, 2020 PubMed10.1681/ASN.2019040433)| false
• Search Google Scholar
• Export Citation

Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, et al.: Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129: 1437–1447, 2017 PubMed

• Crossref
• PubMed
Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, : Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129: 1437–1447, 2017 PubMed10.1182/blood-2016-08-737163)| false
• Search Google Scholar
• Export Citation

Vivarelli M, Pasini A, Emma F: Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366: 1163–1165, 2012 PubMed

• Crossref
• PubMed
Vivarelli M, Pasini A, Emma F: Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366: 1163–1165, 2012 PubMed10.1056/NEJMc1111953)| false
• Search Google Scholar
• Export Citation

Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al.: Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748–756, 2012 PubMed

• Crossref
• PubMed
Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, : Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748–756, 2012 PubMed10.2215/CJN.12901211)| false
• Search Google Scholar
• Export Citation

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, et al.; EAGLE Study Group: C5 convertase blockade in membranoproliferative glomerulonephritis: A single-arm clinical trial. Am J Kidney Dis 74: 224–238, 2019 PubMed

• Crossref
• PubMed
Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, ; EAGLE Study Group: C5 convertase blockade in membranoproliferative glomerulonephritis: A single-arm clinical trial. Am J Kidney Dis 74: 224–238, 2019 PubMed10.1053/j.ajkd.2018.12.046)| false
• Search Google Scholar
• Export Citation

Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, et al.: Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72: 84–92, 2018 PubMed

• Crossref
• PubMed
Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, : Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72: 84–92, 2018 PubMed10.1053/j.ajkd.2017.11.019)| false
• Search Google Scholar
• Export Citation

Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160, 2015 PubMed

• Crossref
• PubMed
Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, ; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160, 2015 PubMed10.1038/ki.2015.227)| false
• Search Google Scholar
• Export Citation

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al.; Conference Participants: Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95: 281–295, 2019 PubMed

• Crossref
• PubMed
Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, ; Conference Participants: Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95: 281–295, 2019 PubMed10.1016/j.kint.2018.11.008)| false
• Search Google Scholar
• Export Citation

Békássy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D: Aliskiren inhibits renin-mediated complement activation. Kidney Int 94: 689–700, 2018 PubMed

• Crossref
• PubMed
Békássy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D: Aliskiren inhibits renin-mediated complement activation. Kidney Int 94: 689–700, 2018 PubMed10.1016/j.kint.2018.04.004)| false
• Search Google Scholar
• Export Citation

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al.: The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 15: 45–59, 2019 PubMed